Consistent, reliable starting, smart load sensing technology, fuel protection and fuel savings are hallmarks of a new 27-gross hp1 Briggs & Stratton Commercial Series Engines with electronic fuel injection (EFI) now available on Simplicity’s Prestige garden tractor. Available at Simplicity dealers this spring, EFI brings several added benefits to a garden tractor model already known for its impressive power, performance and reliability.
“The new Commercial Series V-twin engine with EFI provides more reliable starting,” says Ryan Fredrickson, product manager for consumer rides, Briggs & Stratton Turf & Consumer Products. “Hot or cold, regardless of conditions, the addition of electronic fuel injection offers car-like starting. And because it uses a closed fuel system, EFI helps preserve the fuel, preventing it from going bad and reducing starting issues.
To view the multimedia release go to:
https://www.multivu.com/players/English/8092851-briggs-and-stratton-electronic-fuel-injection-simplicity-prestige-garden-tractor/
Kaléo, a privately-held pharmaceutical company, today announced the AUVI-Q® (epinephrine injection, USP) Auto-injector will be available by prescription starting February 14th, and announced AUVI-Q AffordAbility, a first-of-its-kind access program for AUVI-Q. Through this new program, patients with commercial insurance, even those with high-deductible plans, will have an out-of-pocket cost of $0. For patients who do not have government or commercial insurance, and have a household income of less than $100,000, AUVI-Q will be available free of charge. In addition, the cash price for AUVI-Q is $360 and will be available to those patients without government or commercial insurance. Each AUVI-Q prescription includes two Auto-injectors and one Trainer for AUVI-Q.
To view the multimedia release go to:
http://www.multivu.com/players/English/7981051-auvi-q-epinephrine-auto-injector-access-and-availability-launch/
The following is being released by the Notice Provider, Kinsella Media, LLC, about the lawsuit In re Automotive Parts Antitrust Litigation, MDL No. 2311.
There is an update for affected purchasers in this lawsuit about certain motor vehicle components, as there have been additional Settlements that may affect their rights.
Settlements totaling approximately $225 million have now been reached with eleven Defendants. The lawsuits allege that they fixed the price of certain motor vehicle components, causing millions of consumers and businesses from around the country to overpay for new or leased automobiles and replacement parts, such as air flow meters, alternators, ATF warmers, automotive wire harness systems, electronic throttle bodies, fuel injection systems, fuel senders, heater control panels, high intensity discharge ballasts, ignition coils, instrument panel clusters, inverters, motor generators, occupant safety restraint systems, radiators, starters, steering angle sensors, switches, and valve timing control devices.
To view the multimedia release go to:
http://www.multivu.com/players/English/7755651-auto-parts-antitrust-update/
The following is being released by the Notice Provider, Kinsella Media, LLC, about the lawsuit In re Automotive Parts Antitrust Litigation, MDL No. 2311.
Settlements totaling approximately $54.1 million have been reached with two Defendants. The lawsuits allege that they fixed the price of certain motor vehicle components, causing millions of consumers and businesses from around the country to overpay for new or leased automobiles and replacement parts, such as air flow meters, alternators, ATF warmers, electronic throttle bodies, fuel injection systems, ignition coils, inverters, motor generators, radiators, starters, and valve timing control devices.
The Settlements provide monetary relief for consumers in the District of Columbia and 30 states - Arizona, Arkansas, California, Florida, Hawaii, Iowa, Kansas, Maine, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Mexico, New York, North Carolina, North Dakota, Oregon, Rhode Island, South Carolina, South Dakota, Tennessee, Utah, Vermont, West Virginia, and Wisconsin. The Settlements also provide non-monetary relief, including cooperation, and an agreement by the Defendants not to engage in certain conduct for a period of 24 months.
To view the multimedia release go to:
http://www.multivu.com/players/English/7666751-auto-parts-antitrust-litigation/
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that many retina specialists throughout the U.S. are now using ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg to treat patients with diabetic macular edema (DME). The first injections of ILUVIEN in the U.S. were captured during a live web event attended by more than 250 eye care professionals. ILUVIEN is the first multiyear eye implant designed to deliver a continuous, submicrogram daily dose of steroid to the retina for 36 months with one injection. ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7496251-iluvien-dme/
Chiasma, Inc., a U.S. privately–held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced two new studies presented at the 97th Endocrine Society (ENDO) Annual Meeting in San Diego, Calif. The studies provide additional data from Chiasma’s Phase III trial and new findings on the patient burden of current injection therapies.
“We now have data to help clinicians determine whether octreotide capsules, if approved, are likely to help their patient with acromegaly maintain response,” said Shlomo Melmed, M.D., senior vice president and dean, Cedars–Sinai Medical Center, Los Angeles and global study principal investigator. “Furthermore, the Phase III results show the safety and efficacy of octreotide capsules can be reliably determined within 12 weeks of initiating therapy.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7436451-endo-chiasma-clinical-data/
Jerome Bettis and Robin Miller are teaming up with Sanofi US to raise awareness of life-threatening allergic reactions (anaphylaxis) and spread the word that Auvi-Q™ (epinephrine injection, USP) is now available by prescription in pharmacies nationwide. Bettis, who is allergic to shellfish, and Miller, who is allergic to eggs, hope to help educate adults and caregivers of children at risk for severe allergic reactions.
Auvi-Q is the first-and-only epinephrine auto-injector with audio and visual cues for the emergency treatment of life-threatening allergic reactions in people who are at risk for or have a history of anaphylaxis. The size and shape of a credit card and the thickness of a smart phone, Auvi-Q is a breakthrough in epinephrine auto-injector design that talks patients and caregivers step-by-step through the injection process.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59439-auvi-q-epinephrine-injection-usp-now-available-by-prescription-in-u-s
Novo Nordisk, a world leader in diabetes care, today kicked off the first NovoLog® Community Star contest. As part of the program, type 2 diabetes patients successfully managing their blood sugar with NovoLog® (insulin aspart [rDNA origin] injection) are invited to visit www.novolog.com and tell us how they’re giving back to their local communities.
Now through March 15, NovoLog® patients can submit their story and photo online for the chance to be crowned a NovoLog® Community Star. Finalists will be selected by a panel of judges, and each will receive a $5,000 donation to a local diabetes-related organization of their choice. One grand prize winner will also receive a one-year online subscription to Weight Watchers® to help with their diabetes management.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59947-novo-nordisk-first-novolog-community-star-contest-type-2-diabetes-patients
The production version of the new three-row, six/seven-passenger Santa Fe makes its world debut today at the 2012 Los Angeles Auto Show, joining the two-row, five-passenger Santa Fe Sport which has been on sale since August. The all-new Santa Fe delivers Hyundai’s recipe of bold design, high-output powertrains with Gasoline Direct Injection (GDI) and a host of features to please drivers and passengers with high expectations for functionality, versatility and comfort. Pricing will be announced closer to the on-sale date early next year.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59332-hyundai-2013-six-seven-passenger-santa-fe-2012-los-angeles-auto-show
dr samit sekhar - Indian Surrogacy : Executive Director of Kiran Infertility Centre Pvt. Ltd.(KIC), he also holds positions of IVF and Surrogacy Program Director , Director- Supra Sperm Semen Bank and is also the Chief Embryologist in KIC. With an experience of more than 5 Years in the field of Infertility, he has treated a clientele of more than 2000 IVF/ ICSI Patients and 800 Surrogacy Patients from 21 different countries. In charge of the overall maintenance of the IVF lab he is also involved in day to day patient interaction and counseling He passed his Bachelors in medicine in distinction. His expertise includes In-Vitro Fertilization (IVF), Intra Cytoplasm Sperm Injection (ICSI), Embryo Freezing (Vitrification), Semen Banking (Semen Freezing) and PIGD (Pre-Implanation Genetic Diagnosis). Dr. Samit has been instrumental in bringing India on the Medical Tourism World Map as Surrogacy Capital of world. Under his leadership there have been 221 births through Surrogacy Program in KIC for Intended Parents of 17 different countries. Different from what people imagine a Doctor should be. love to live life on my own terms, I think out of the box.
